0000000000815611

AUTHOR

R. Rubin

showing 2 related works from this author

Searches for lepton number violation and resonances in K± → πμμ decays

2017

The NA48/2 experiment at CERN collected a large sample of charged kaon decays to final states with multiple charged particles in 2003–2004. A new upper limit on the rate of the lepton number violating decay K±→π∓μ±μ± is reported: B(K±→π∓μ±μ±)<8.6×10−11 at 90% CL. Searches for two-body resonances X in K±→πμμ decays (such as heavy neutral leptons N4 and inflatons χ ) are also presented. In the absence of signals, upper limits are set on the products of branching fractions B(K±→μ±N4)B(N4→πμ) and B(K±→π±X)B(X→μ+μ−) for ranges of assumed resonance masses and lifetimes. The limits are in the (10−11,10−9) range for resonance lifetimes below 100 ps.

leptonBEAM01 natural sciences7. Clean energyPhysics Particles & FieldsHigh Energy Physics - ExperimentLIMITSkaon physicsCERNIntermediate statelepton number violation neutrinos dark matter kaon physicsPhysicsVMSMLarge Hadron ColliderPhysicsCharge KaonsneutrinosNuclear and High Energy Physics; CERN; leptonsHigh Energy Physics - Experiment; Charge Kaons; Lepton number violationNuclear & Particles PhysicsCharged particlelcsh:QC1-999NEUTRAL HEAVY-LEPTONSPhysics Nuclearlepton number violationPhysical SciencesParticle physicsNuclear and High Energy Physicsleptonskaon decays lepton number violationNuclear and High Energy Physics lepton kaon meson lepton number violation NA48Socio-culturaleAstronomy & AstrophysicsUPPER-BOUNDSdark matterNuclear physics0202 Atomic Molecular Nuclear Particle And Plasma Physics0103 physical sciencesDARK-MATTERPARTICLES010306 general physicsScience & Technologykaon decays010308 nuclear & particles physicsBranching fractionResonanceInflatonLepton numberkaon mesonNA48High Energy Physics::Experimentlcsh:PhysicsLepton
researchProduct

Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A…

2013

International audience; Background & AimsTreatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy. We assessed the effects of these anemia management strategies on rates of sustained virologic response (SVR) and safety.MethodsPatients (n = 687) received 4 weeks of peginterferon and ribavirin followed by 24 or 44 weeks of boceprevir (800 mg, 3 times each day) plus peginterferon and ribavirin. Patients who became anemic (levels of hemoglobin approximately ≤10 g/dL) during the study treatment period (n = 500) were assigned to groups that were managed by ribavi…

Maleviruses[SDV]Life Sciences [q-bio]Hepacivirusmedicine.disease_causeGastroenterologyPolyethylene Glycolslaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawErythropoiesisIncidenceGastroenterologyDisease Managementvirus diseasesAnemiaMiddle AgedRecombinant Proteins3. Good healthTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyAlgorithmsmedicine.drugmedicine.medical_specialtyGenotypeProlineSide effectAnemiaHepatitis C virusInterferon alpha-2Antiviral Agents03 medical and health sciencesInternal medicineBoceprevirRibavirinmedicineHumansErythropoietinDAADose-Response Relationship DrugHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicbiochemical phenomena metabolism and nutritionmedicine.diseasedigestive system diseasesSide EffectLogistic ModelschemistryErythropoietinImmunologyHemoglobinbusinessEPO
researchProduct